Tecentriq atezolizumab: Additional Phase II data

Data from a cohort 1 of the open-label, international Phase II IMvigor210 trial in 119 evaluable patients with locally advanced or metastatic urothelial carcinoma in

Read the full 258 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE